Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Genmab AS's Goodwill for the quarter that ended in Jun. 2026 was kr2,304 Mil. Genmab AS's Total Assets for the quarter that ended in Jun. 2026 was kr81,226 Mil.
Therefore, Genmab AS's Goodwill to Asset Ratio for the quarter that ended in Jun. 2026 was 0.03.
Genmab AS (CHIX:GMABc) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Genmab AS Goodwill-to-Asset Related Terms
Genmab AS Goodwill-to-Asset Historical Data
* Premium members only.
The historical data trend for Genmab AS's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, MRNA: Goodwill-to-Asset Comparison
For the Biotechnology subindustry, Genmab AS's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Goodwill-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Genmab AS's Goodwill-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABC) has a Goodwill-to-Asset of 0.03 as of Jun. 2026. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Genmab AS and its competitors.
Is Genmab AS's Goodwill-to-Asset too high?
Genmab AS's current Goodwill-to-Asset is 0.03. Overall, Genmab AS has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Goodwill-to-Asset compare to VRTX and REGN?
Genmab AS's Goodwill-to-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Genmab AS and its competitors. Genmab AS's current Goodwill-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,158.77, compared to a current price of kr2,179.00 — trading 0.9% above its estimated fair value. The current Goodwill-to-Asset is 0.03. Genmab AS's overall GF Score™ is 96/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Goodwill-to-Asset is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be overvalued.
The current stock price of kr2,179.00 is trading 0.9% above its estimated GF Value™ of kr2,158.77.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
Goodwill-to-Asset: 0.03
GF Value™: kr2,158.77 vs. price of kr2,179.00 (0.9% above fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
96GF Score
Get the complete analysis for CHIX:GMABC
Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
